Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
Completed · Phase 2 · NCT05014815
Conditions: Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
At a glance
- Research payments reported, 2025
- $208,831
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 272
About the trial
- Sponsor
- BeiGene
- Tested
- Ociperlimab (drug), Tislelizumab (drug), Carboplatin (drug), Paclitaxel (drug), Nab paclitaxel (drug), Cisplatin (drug), Pemetrexed (drug), Placebo (drug)
- Dates
- Started 2021-11-16; completion 2024-09-04
- Results posted
- Yes
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surgery, or had spread to other parts of the body.
From ClinicalTrials.gov, last updated 2025-09-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene, Ltd. reported $208,831 in research payments for this study in 2025 (6 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David Berz, MD, PHD, MPH Hematology & Oncology · Los Angeles, CA
- Muhammad Furqan, M.D Medical Oncology · Oklahoma City, OK
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Iowa Hospital & Clinics, IA $196,203
- Valkyrie Clinical Trials, Inc $12,628
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.